Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Dassault Systèmes Launches Three Industry Solution Experiences for Life Sciences

Pharmaceutical and Biotechnology Companies Can Now Digitally Transform Therapeutic Innovation   VELIZY-VILLACOUBLAY, France — November 16, 2015 — Dassault Systèmes (Euronext Paris: #13065, DSY.PA), the 3DEXPERIENCE Company, world leader in 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions, today announced the launch of three industry solution experiences for life sciences, […]

Read More »

Exclusive: U.S. drug benefit managers clamp down on specialty pharmacies

In recent days, the largest U.S. managers of private prescription drug benefits have cut off at least eight pharmacies that work closely with drugmakers, intensifying scrutiny of a system that helps inflate drug prices, officials at the benefit managers told Reuters. The terminations come from payers who together manage drug benefits for more than 100 […]

Read More »

FDA approves Baxalta’s drug for rare bleeding disorder

The U.S. Food and Drug Administration said on Friday it approved Baxalta Inc’s drug for use in patients with a type of rare bleeding disorder. The drug, Adynovate, was approved to control and reduce the frequency of bleeding episodes in patients with Hemophilia A, the agency said in a statement. Data from a late-stage study, […]

Read More »

U.S. approves AstraZeneca’s potential $3 billion lung cancer pill

A new lung cancer pill from AstraZeneca, designed for patients whose disease has worsened after treatment with other therapies, was approved by U.S. regulators on Friday, in a boost for the British drugmaker.   Tagrisso, also known as AZD9291, is one of several cancer medicines AstraZeneca hopes will rebuild its sales following patent losses on […]

Read More »

Panel recommends Merck & Co. continue cholesterol drug study

Merck & Co said an independent data monitoring committee recommended that the drugmaker continue a study of its experimental cholesterol drug, anacetrapib. The recommendation comes a month after Eli Lilly & Co stopped testing a similar cholesterol drug, belonging to a class of drugs called CETP inhibitors. Merck said on Friday that the committee reviewed […]

Read More »

Merck to buy Harrisvaccines to boost livestock vaccine portfolio

Merck & Co Inc’s animal health unit will buy privately held Harrisvaccines Inc to expand its portfolio of animal vaccines as the U.S. livestock industry seeks new defenses against diseases, the companies said on Thursday. Financial details were not disclosed. The deal, which is expected to close by year-end, follows rival Zoetis Inc’s agreement, announced […]

Read More »

Roche Exiting Four Manufacturing Sites in Europe and the U.S.,1,200 Jobs Impacted

November 12, 2015By Alex Keown, Breaking News Staff   BASEL, Switzerland – Roche (RHHBY) will vacate four manufacturing sites in the United States and Europe, displacing approximately 1,200 employees as part of a restructuring effort for the manufacturing of its small molecule products, the company announced Thursday. The move comes as Swiss-based Roche addresses […]

Read More »

U.S. FDA approves Gilead’s hepatitis C drug for expanded use

Drugmaker Gilead Sciences Inc said on Thursday the U.S. Food and Drug Administration had approved the expanded use of its blockbuster hepatitis C drug, Harvoni.   The drug can now be used to treat patients with subtypes of chronic hepatitis C virus (HCV) and patients who are co-infected with Human Immunodeficiency Virus (HIV), Gilead said […]

Read More »

Injuries may be more common in kickboxing than other sports

Injuries may be more common in kickboxing than in traditional boxing, mixed martial arts or other contact sports, a recent study suggests. On average, kickboxing has an injury rate of about 40 for every 1,000 minutes of playing time, or about 2.5 injuries an hour, the study of U.S. competitions found. That’s about as dangerous […]

Read More »

New York City finds one in five adults has mental health problems

At least one in five adult New Yorkers suffer from depression, substance abuse, suicidal thoughts or other psychological disorders every year, according to a report released on Thursday ahead of Mayor Bill de Blaiso’s new mental-health initiative.   New York City’s Department of Health and Mental Hygiene expects to release the plan, known as NYC […]

Read More »

Pacific trade deal could limit affordable drugs: world health chief

A massive trade pact between 12 Pacific rim countries could limit the availability of affordable medicines, the head of the World Health Organization said on Thursday, joining a heated debate on the impact of the deal.   Margaret Chan told a conference there were “some very serious concerns” about the Trans-Pacific Partnership (TPP), a central […]

Read More »

Novartis, Roche find ‘outcome-based’ drug pricing an elusive dream

News that Novartis’s heart drug Entresto cuts the risk of re-hospitalization might have helped Chief Executive Joe Jimenez realize his ambition of getting insurers to pay more for treatments when they cut overall medical costs. Instead Jimenez and Severin Schwan, CEO of cross-town rival Roche, have been forced to concede that insurance companies, especially in […]

Read More »

Derma Sciences to stop tests on only experimental drug, shares slump

Derma Sciences Inc said it would stop tests on its only drug in development after an outside assessment showed the drug was unlikely to heal foot ulcers caused by diabetes. The company’s shares slumped about 25 percent premarket on Thursday. Derma Sciences, which already has drugs on the market, said it will also stop developing […]

Read More »

China rejects 11 drug applications over inadequate trial data

China has signaled a tougher stance on drug quality in the country’s sprawling pharmaceuticals industry by rejecting applications for 11 medicines with inadequate or suspect clinical data. The China Food and Drug Administration (CFDA) said in statement posted on its website on Nov. 11 that the move affected eight Chinese companies making generic drugs for […]

Read More »

So Long, Stethoscope? New Device And IPhone Alter Exams, Study

Orlando, Florida – The iconic stethoscope we’ve become accustomed to seeing draped around the necks of doctors and healthcare providers may someday be replaced by smartphones and a new portable device, called HeartBuds, that is slightly larger than a quarter. “They not only detect sounds inside the body just as well – or better – […]

Read More »

Germany, U.S. in hot pursuit of ‘messenger’ drug molecules

A molecule that carries the recipe for making drugs inside body cells is exciting scientists and investors alike, attracting hundreds of millions of dollars in a scramble for the next promising area of biotechnology. German and U.S. firms are leading the way in synthetic messenger RNA, or mRNA technology, a new approach to tackling a […]

Read More »

Clinical Trial Results Disclosure by Large Biopharmaceutical Companies Falls Below Legal and Ethical Standards, Study Published in BMJ Open Shows

Study Conducted by Bioethics International Debuts Good Pharma Scorecard – an Integrity Ranking for the Healthcare Industry   NEW YORK, Nov. 12, 2015 /PRNewswire/ — Bioethics International, a not-for-profit organization focused on the ethics and governance of how medicines are researched, developed, marketed and made accessible to patients around the world, today announced the publication of […]

Read More »

Allergan CEO Finds Valeant Business Model Incompatible

November 12, 2015By Mark Terry, Breaking News Staff   Now that Pfizer Inc. (PFE) is in friendly talks to acquire Allergan (AGN), analysts are interested in what Allergan chief executive officer Brent Saunders thinks about Valeant Pharmaceuticals International Inc. (VRX). In April 2014, Valeant and Bill Ackman’s New York hedge fund, Pershing Square Capital […]

Read More »

Portola reversal agent for Xarelto succeeds in late stage trial

A drug developed by Portola Pharmaceuticals to rapidly reverse the effect of new blood thinning agents in cases of major bleeding or other emergencies proved highly effective in a late stage study, according to data presented on Wednesday that should help make the case for its approval. Portola’s andexanet alfa reversed the anticoagulant effect of […]

Read More »

Alnylam, Medicines Co cholesterol drug effective for six months: study

An experimental cholesterol fighter being developed by Alnylam Pharmaceuticals and The Medicines Co slashed levels of bad LDL cholesterol and remained effective for six months, according to data from a small, early stage study. The drug, called ALN-PCSsc, cut LDL by more than 50 percent in the 69-subject study presented at the American Heart Association […]

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!


Ad Right Bottom